Skip to content
Search

Latest Stories

Bharat Biotech’s Covaxin in Oman's list of approved vaccines

Bharat Biotech’s Covaxin in Oman's list of approved vaccines

BHARAT Biotech's Covaxin has been included in the approved list of Covid-19 vaccines for travel to Oman without quarantine.

In a tweet, Bharat Biotech said: "Covaxin has now been added to the approved list of #COVID19 vaccines for travel to Oman without quarantine. This will facilitate travellers from India vaccinated with Covaxin."


It cited a press release issued by the Embassy of India, Muscat, in this regard.

"Embassy of India, Muscat, is pleased to inform that the Government of the Sultanate of Oman has added Covaxin to the approved list of Covid-19 vaccines for travel to Oman. The Civil Aviation Authority issued a notification on 27 October regarding this," the release stated.

All passengers from India who have received two doses of Covaxin at least 14 days before the estimated arrival date will now be able to travel to Oman without the requirement of quarantine, it added.

All other Covid-19 related requirements such as pre-arrival RT-PCR test shall be applicable for such passengers, the release stated.

This notification will significantly ease travel to Oman for Indian nationals who have taken Covaxin, it noted.

Passengers who have taken AstraZeneca/Covishield are already permitted to travel to Oman without quarantine.

(PTI)

More For You

Fujitsu
Fujitsu won £1.4 bn government contracts since 2019
AFP via Getty Images

Fujitsu denies ‘parasite’ claim over Post Office contracts

TECH firm Fujitsu has defended its continued work with the UK government following the Post Office Horizon scandal, rejecting claims that it is unfairly profiting from one of the biggest miscarriages of justice in the country's history.

Speaking to MPs on the Business and Trade Committee, Fujitsu’s European chief executive Paul Patterson said the company was “not a parasite”, despite receiving around £500 million in contract extensions linked to government work.

Keep ReadingShow less